Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome
Sign Up to like & getrecommendations! Published in 2023 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.55709
Abstract: Key Points Question Is short-term oral rivaroxaban a noninferior alternative to parenteral enoxaparin in the acute phase of acute coronary syndrome (ACS)? Findings This equivalence and noninferiority trial including 2046 patients found that short-term rivaroxaban… read more here.
Keywords: coronary syndrome; acute phase; acute coronary; phase acute ... See more keywords